Business
Admission of ProBiotix Health plc to AQSE
Admission of ProBiotix Health plc to AQSE.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6542G\n OptiBiotix Health PLC\n 31 March 2022\n \n \n \n OptiBiotix Health plc\n (\"OptiBiotix\" or the \"Company\")\n \n Admission of ProBiotix Health plc to AQSE Growth Market\n \n \n OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the admission of its former subsidiary, ProBiotix Health plc (AQSE: PBX), onto the AQSE Growth Market. \n \n \n \n \n \n As part of the Admission, ProBiotix Health plc (\"ProBiotix\" or \"PBX\") has raised £2.5 million through a placing and subscription of 11,904,762 Ordinary Shares at a price of 21p per share. A total of 121,666,666 ordinary shares of 0.05p each in PBX (\"Ordinary Shares\") will be admitted to trading on the Access Segment of the AQSE Growth Market (\"Admission\") today valuing ProBiotix at approximately £25.5m. \n \n \n \n \n PBX has a unique strain of Lactobacillus plantarum trademarked as LPLDL which three clinical studies published in peer reviewed journals have shown statistically significant changes to clinically important cardiovascular risk including total cholesterol, LDL (bad) cholesterol, and Apolipoprotein B. The company also has six publications showing LPLDL's mechanism of action and 27 patents and 22 trademarks protecting its commercial interests, and FDA GRAS which allows the use of LPLDL in food products.\n \n \n \n \n OptiBiotix recently announced (RNS: 28 February 2022) that preliminary unaudited results for PBX for the year ended 31 December 2021, indicated total sales of £1.1 million.\n \n \n \n Distribution\n \n The Company is pleased to confirm that OptiBiotix shareholders on the register as at close of business on 25 March 2022 (\"Record Date\") will receive 0.554673 ProBiotix share for every one OptiBiotix ordinary share held. Entitlements will be rounded down to the nearest whole number of PBX Shares. The legal title to the Dividend Shares will be held by Global Prime Partners Nominees Ltd acting as nominee on behalf of each of the Qualifying Shareholders (\"Nominee\") and an 'omnibus' share certificate in respect of the Dividend Shares. The Nominee will hold the Dividend Shares on trust for each of the Qualif...